MonumenTAL-1: Talquetamab in Relapsed/Refractory MM

Opinion
Video

Donna Catamero, ANP-BC, OCN, CCRC, reviews findings from the MonumenTAL-1 study and the panel provides its impressions of the results.

This is a video synopsis/summary of a Between the Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.

Results from the phase 1/2 MonumenTAL-1 trial (NCT03399799) led to FDA approval of talquetamab, a GPRC5D-targeting bispecific antibody, for relapsed/refractory multiple myeloma (MM) after at least 3 prior lines including proteasome inhibitors, immunomodulators, and anti-CD38 antibodies. Patients received step-up dosing of talquetamab 0.4 mg/kg weekly, 0.8 mg/kg every other week, or either schedule after prior T-cell redirection therapy. Overall response rates were 72% to 74% (65% after prior therapy), very good partial response or better rate was 65% (55% after prior therapy), median progression-free survival was 5.1 to 14.2 months, and 12-month duration of response rates for complete response were 79% to 90%. Adverse events included cytokine release syndrome, dysgeusia, dermatologic toxicity, and cytopenias. Infection rates were 59% to 73% (higher after prior therapy).

Rodriguez found talquetamab efficacy and durability comparable to BCMA-directed treatments. Usmani welcomed talquetamab while noting the need for sequencing data between GPRC5D and BCMA targets. Limitations include lack of patients with high-risk disease features to inform effectiveness in these groups.

Video synopsis is AI generated and reviewed by CancerNetwork® editorial staff.

Recent Videos
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Related Content